Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Suceagu – page 12

447 clinical trials in Suceagu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Suceagu at a glance
447
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

447 trials in Suceagu

Open in trial search

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Study on the Safety and Effectiveness of HDP-101 for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:HDP-101
  • Sponsor:Heidelberg Pharma AG

Study on the Effects of Cerebrolysin and Sodium Chloride for Recovery in Patients with Moderate to Severe Traumatic Brain Injury

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Foundation For The Study Of Nanoneuroscience And Neuroregeneration

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on the Effectiveness of INM004 for Children with Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing E. coli

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:EQUINE SHIGA TOXIN 1/2 IMMUNE FAB2
  • Sponsor:Chemo Research S.L.

Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Suceagu

What the registry says about research in the country

01 Female Urogenital Diseases and Pregnancy Complications

In Suceagu, clinical research in female urogenital diseases is focused on improving care for stress urinary incontinence. The trials are looking at whether new treatment approaches can better reduce symptoms and support daily comfort for women living with this condition.

  • Stress urinary incontinence
  • Female urogenital health
  • Symptom control and quality of life
  • Evaluating a new therapy approach

This area reflects a practical effort to find more effective options for a common and often disruptive condition.

02 Neoplasms

Cancer research in this city includes studies in non-small cell lung cancer, with attention on patients who have HER2 mutations. The work is aimed at determining whether a targeted treatment can improve outcomes compared with standard care after surgery.

  • Non-small cell lung cancer
  • HER2-mutated tumors
  • Post-surgical cancer care
  • Testing treatment effectiveness

This field highlights efforts to advance more precise cancer treatment strategies and strengthen long-term disease control.

03 Metabolic and Urologic Symptom Research

Another active focus combines obesity or overweight with urinary incontinence, reflecting interest in how weight-related health issues may affect urinary symptoms. The research is designed to see whether a new therapy can better improve patient-reported outcomes.

  • Obesity and overweight
  • Urinary incontinence
  • Women’s health
  • Improving symptom outcomes

These studies bring together metabolic and urologic care in a way that may help guide more personalized treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.